|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Ten patients with early AD underwent NGF gene therapy using ex vivo or in vivo gene transfer.
|
26302439 |
2015 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Most Tg AD models, which at least partly recapitulate the AD phenotype, are based on insertion of one or more human mutations (identified in Familial AD) into the mouse genome, with the notable exception of the anti-NGF mouse, which is based on the cholinergic unbalance hypothesis.
|
21732714 |
2011 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We designed a case-control association study to test the hypothesis as to whether polymorphisms located in the proNGF genomic region influence the liability to Alzheimer's disease and its prodromal form, mild cognitive impairment.
|
22330829 |
2012 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Regarding the functional roles of neurotrophin polymorphisms as they relate to executive dysfunction, the NGF gene rs6330 might influence the inhibition task in Japanese patients with early-stage AD or A-MCI.
|
22301435 |
2011 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to validate the association of the five AD-associated variants, 8-oxoguanine DNA glycosylase 1 (<i>OGG1</i>) rs1052133, bridging integrator 1 rs744373, sortilin-related receptor 1, rs1133174, presenilin 2 rs8383, and nerve growth factor rs6330, in the Xinjiang Chinese population.
|
30214536 |
2018 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
No differences in the number of NGF-R mRNA-positive neurons between normal aged and AD patients were detected within the NGF-responsive cell groups of the medial septum (Ch1) and nucleus of the vertical limb of the diagonal band (Ch2).
|
2556292 |
1989 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Cardiolipin (CL)-conjugated LIP carrying CRM (CRM-CL/LIP) and also carrying NGF (NGF-CL/LIP) were used with AD models of SK-N-MC cells and Wistar rats after an insult with β-amyloid peptide (Aβ).
|
28280340 |
2017 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To determine serum concentrations of a panel of neurotrophic factors (BDNF, NGF, and GDNF) in a cross-section of elderly patients with mild cognitive impairment (MCI) and AD compared to cognitively healthy controls, and to evaluate whether abnormal levels of these factors at baseline predict the transition from MCI to dementia.
|
25737042 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Those results strongly suggest that SpBMP-9 plus NGF or bFGF are promising therapeutic combinations against AD that required further attention.
|
29341901 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This work demonstrates a new concept of using thermoresponsive and biodegradable linear-dendritic nanoparticles for thermally targeted and sustained release of NGF and other protein drugs for the treatment of Alzheimer's disease and other neurological disorders.
|
29320631 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Different growth factors affect distinct and specific populations of neurons: the first nervous system growth factor identified, nerve growth factor, potentially stimulates the survival and function of basal forebrain cholinergic neurons, suggesting that nerve growth factor could be a means for reducing the cholinergic component of cell degeneration in Alzheimer disease.
|
17545746 |
2007 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Decreased cortical NGF immunocytochemical scores of AD-like model were increased by CE (p<0.05).
|
28390878 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results showed that: (1) APP/PS1-AD mice had lower spontaneous alternation in the Y-maze than wild-type (WT) mice, and this was significantly reversed by AVP(4-8); (2) the prolonged escape latency of APP/PS1-AD mice in the Morris water maze was significantly decreased by AVP(4-8), and the decreased swimming time in target quadrant recovered significantly after AVP(4-8) treatment; (3) in vivo hippocampal LTP induced by high-frequency stimulation had a significant deficit in the AD mice, and this was partly rescued by AVP(4-8); (4) AVP(4-8) significantly up-regulated the expression levels of postsynaptic density 95 (PSD95) and nerve growth factor (NGF) in the hippocampus of AD mice.
|
31605298 |
2020 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review covers the main therapeutic approaches that have been developed for NGF delivery targeting the brain, from polymeric implants to gene and cell-based therapies, focusing on the role of nanoparticulate systems for the sustained release of NGF in the brain as a neuroprotective and disease-modifying approach toward AD.
|
28351757 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This anabolic growth factor has been delivered into the forebrain of patients with mild Alzheimer's disease using transfer of autologous fibroblasts engineered to produce nerve growth factor.
|
16022580 |
2005 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results obtained with the AD11 anti-NGF mice highlight the fact that the particular mode of NGF neutralization, with an NGF antibody expressed in the brain, selectively interfering with mature NGF versus unprocessed proNGF, plays a major role in the mechanism of neurodegeneration, and could lead to new insights into the mechanisms of human sporadic AD.
|
21631402 |
2011 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated a shift in the balance of NGF and its receptors toward cell death mechanisms during the progression of AD.
|
21397006 |
2011 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Additional clinical trials of NGF for Alzheimer disease are warranted.
|
15852017 |
2005 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we provide evidence that: (i) NGF could be one of the "routing" proteins responsible for modulating the metabolism of APP from amyloidogenic towards non-amyloidogenic processing via binding to the TrkA receptor; (ii) the loss of NGF/TrkA signaling could be linked to sporadic AD contributing to the classical hallmarks of the neuropathology, such as synaptic loss, β-amyloid peptide (Aβ) deposition and tau abnormalities.
|
28632177 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor (NGF), a potent survival factor for critical cell populations that degenerate in AD, has been chosen already for clinical gene therapy trials in human AD patients.
|
16719061 |
2006 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The development of hNGF-61 towards clinical applications in AD patients is under way.
|
19355851 |
2009 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
RGD |
Brain and serum levels of nerve growth factor in a rat model of Alzheimer's disease.
|
21368378 |
2011 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies.
|
24112788 |
2014 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, MEM treatment activated the NGF/TrkA signaling, and inhibited the p75(NTR) signaling in APP/PS1 mice to ameliorate the behavioral deficits and amyloidosis, indicating that NGF signaling was a new potential target of MEM treatment for AD therapy.
|
24846616 |
2014 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor (NGF) has a great potential for the treatment of Alzheimer's disease.
|
19221427 |
2009 |